2 citations
,
November 2017 in “Gynecological Endocrinology” This study found that serum myo-inositol oxygenase levels do not differ between women with polycystic ovary syndrome and healthy controls, suggesting that MI deficiency in PCOS is not due to MIOX levels.
369 citations
,
June 2013 in “Biochimie” This review discusses the potential benefits of myo-inositol supplementation for insulin resistance-related disorders and diabetic complications, but reports no new clinical results.
October 2023 in “Frontiers in endocrinology” This review investigates molecular mechanisms behind PCOS pathogenesis and discusses potential therapies, but reports no new clinical results.
1 citations
,
August 2025 in “International Journal of Molecular Sciences” This narrative review suggests that nutraceutical insulin-sensitizing agents like myo-inositol, alpha-lipoic acid, and vitamins may improve glycemic control and reduce inflammation in insulin resistance-related skin disorders; however, more robust long-term trials are needed to confirm these findings and establish treatment regimens.
December 2023 in “Frontiers in endocrinology” This review explores the role of hyperandrogenism, including adrenal-derived 11-oxygenated androgen, in the development of polycystic ovarian syndrome and discusses potential therapeutic strategies targeting androgen excess, without reporting new clinical results.